{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002424","form_type":"8-K","ticker":"UFPT","cik":"0000914156","company_name":"UFP TECHNOLOGIES INC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.428833+00:00","generated_at":"2026-06-03T03:46:06.694460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UFP Technologies Q1 net income up 30% to $12.7M; EPS $1.64; sales $105M (+7.4%)","bullets":["Diluted EPS of $1.64 vs $1.27 in Q1 2023; net income $12.7M vs $9.7M.","Revenue $105.0M, up 7.4% YoY; medical market sales $90.0M (+7.4%); other markets $15.0M (+7.4%).","Operating income grew 24% to $15.9M; adjusted EBITDA $20.7M (+6.5%); gross margin 28.6% (down from 29.4%).","CEO cites growth in robotic surgery and infection prevention; Mexico sales up 47%; Dominican Republic expansion complete.","Balance sheet with ~$34M debt; active acquisition pipeline with multiple projects in due diligence."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002424","json":"https://secwatch.observer/filing/0001171843-24-002424.json","markdown":"https://secwatch.observer/filing/0001171843-24-002424.md","text":"https://secwatch.observer/filing/0001171843-24-002424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914156/000117184324002424/0001171843-24-002424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914156/000117184324002424/f8k_050124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:46:06.694460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7691ed6f0c5d2e6cc351a957f357add6835b6c74","claim":"UFP TECHNOLOGIES INC reported first quarter ended March 31, 2024 results: revenue $105.0 million, net income $12.7 million, EPS $1.64 per diluted common share outstanding.","evidence_excerpt":"UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of comprehensive solutions primarily for the medical market, today reported net income of $12.7 million or $1.64 per diluted common share outstanding for its first quarter ended March 31, 2024, compared to net income of $9.7 million or $1.27 per diluted common share outstanding for the first quarter of 2023. Net Sales for the first quarter were $105.0 million compared to 2023 first quarter sales of $97.8 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914156/000117184324002424/0001171843-24-002424-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$105.0 million"},{"label":"Net income","value":"$12.7 million"},{"label":"EPS","value":"$1.64 per diluted common share outstanding"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}